Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Enzalutamide · Xtandi, MDV-3100

Small molecule · Antagonist of androgen receptor (AR) · developed by Astellas

Approved FDA, Aug 2012
1 Registered trials

What is Enzalutamide?

Enzalutamide is an oral androgen receptor inhibitor that competitively blocks androgen binding, prevents nuclear translocation of the receptor and its interaction with DNA. It is studied in and used for prostate cancer, including castration-resistant and castration-sensitive disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Xtandi, MDV-3100
Drug type
Small molecule
Targets
androgen receptor (AR)
Mechanism
Antagonist of androgen receptor (AR)
Pathways
androgen receptor signaling, androgen binding and nuclear translocation, androgen receptor DNA interaction
Therapy area
Oncology
Developer
Astellas
In trials of
NVS
FDA status
Approved as Xtandi (August 31, 2012), NDA203415 · FDA label
UNII
93T0T9GKNU

✅ FDA-approved uses

From the indications section of the FDA label (version of Jul 28, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06894511 Phase 2 Metastatic Castration Resistant Prostate Cancer (mCRPC) Active not recruiting NVS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Other drugs acting on AR

Sources

Updated Nov 15, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.